© Reuters. Arrival of AstraZeneca vaccines in Canada
(Reuters) – Canada on Saturday reported a second case of rare blood clots with low platelets after immunization with AstraZeneca’s (NASDAQ 🙂 COVID-19 vaccine in a week, while saying it still recommends the use of the vaccine.
The person who experienced this very rare event has been treated and is recovering, Canada’s Department of Health said in a statement, adding that the person lives in the province of Alberta.
Based on the available evidence, Canada still maintains that the benefits of the AstraZeneca vaccine outweigh the potential risks, the statement said.
Canadian health authorities “will continue to closely monitor the use of all COVID-19 vaccines and review and assess any emerging safety issues,” the statement said.
Canada reported an initial blood clotting associated with the vaccine on Tuesday and a day later, after a review, health officials said they would not restrict the use of the AstraZeneca vaccine.
A separate advisory board had previously recommended that Canada stop offering the vaccine to people under the age of 55. This group is reviewing their advice.
Canada has stepped up its vaccination campaign, but still has a lower percentage of its population vaccinated than dozens of other countries, including the United States and Great Britain.
Amid a third surging wave of infections, Ontario, Canada’s most populous province, announced new public health restrictions on Friday, including closing the province’s borders to domestic travelers.
Fusion Media or anyone involved with Fusion Media will not accept any responsibility for loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.